Benitec Biopharma (NASDAQ:BNTC) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Benitec Biopharma (NASDAQ:BNTC) in a report published on Monday morning,Benzinga reports. They currently have a $28.00 price objective on the biotechnology company’s stock.

BNTC has been the topic of a number of other research reports. Robert W. Baird started coverage on Benitec Biopharma in a report on Friday, December 13th. They set an “outperform” rating and a $30.00 price target on the stock. Guggenheim reissued a “buy” rating and issued a $17.00 price target on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. Finally, Baird R W upgraded shares of Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $24.43.

Benitec Biopharma Stock Down 11.0 %

Shares of NASDAQ BNTC opened at $14.34 on Monday. The firm’s 50-day moving average price is $11.99 and its two-hundred day moving average price is $11.01. Benitec Biopharma has a 52-week low of $4.75 and a 52-week high of $16.90. The stock has a market capitalization of $336.29 million, a P/E ratio of -9.50 and a beta of 0.92.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.19. As a group, equities research analysts expect that Benitec Biopharma will post -1.48 earnings per share for the current year.

Institutional Investors Weigh In On Benitec Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Suvretta Capital Management LLC increased its stake in Benitec Biopharma by 422.0% in the 3rd quarter. Suvretta Capital Management LLC now owns 8,829,053 shares of the biotechnology company’s stock worth $81,139,000 after purchasing an additional 7,137,763 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Benitec Biopharma by 269.0% in the fourth quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company’s stock worth $37,123,000 after buying an additional 2,142,643 shares during the period. Janus Henderson Group PLC increased its position in shares of Benitec Biopharma by 198.5% in the fourth quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company’s stock worth $33,268,000 after acquiring an additional 1,739,904 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Benitec Biopharma by 134.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company’s stock valued at $24,913,000 after acquiring an additional 1,131,129 shares during the period. Finally, Infinitum Asset Management LLC purchased a new stake in shares of Benitec Biopharma in the 4th quarter valued at approximately $2,652,000. 52.19% of the stock is owned by institutional investors and hedge funds.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.